[ RadSafe ] American Medical Isotopes Production Act of 2009 willensure reliable medical isotope supply

Franta, Jaroslav frantaj at aecl.ca
Mon Nov 9 08:00:42 CST 2009


UNRESTRICTED | ILLIMITÉ

So where was the Society of Nuclear Medicine when FFTF was being shut down for good ??

How many billions will the new reactor cost ?

Send your paycheques to Congressman Edward J. Markey (D–MA)

Jaro
^^^^^^^^^^^^^^^^^^^^


-----Original Message-----
From: radsafe-bounces at radlab.nl [mailto:radsafe-bounces at radlab.nl]On
Behalf Of ROY HERREN
Sent: November 8, 2009 10:58 PM
To: radsafe at radlab.nl
Subject: [ RadSafe ] American Medical Isotopes Production Act of 2009
willensure reliable medical isotope supply


Public release date: 6-Nov-2009
Contact: Amy Shaw
ashaw at snm.org
703-652-6773
Society of Nuclear Medicine 

SNM applauds House action to build medical isotopes reactor in the US
American Medical Isotopes Production Act of 2009 will ensure reliable medical isotope supply
Reston, Va.—SNM applauds the U.S. House of Representatives for its passage of H.R. 3276—the American Medical Isotopes Production Act of 2009.
"The worldwide isotope shortage has long been adversely affecting patients in the U.S.," said Michael M. Graham, Ph.D., M.D., president of SNM. "This important legislation will bring us one step closer to solving this chronic problem."
The American Medical Isotopes Production Act of 2009 was introduced by Congressman Edward J. Markey (D–MA) in July. 
"Congressman Markey has worked closely with the medical community, members of industry and other stakeholders to ensure that this important legislation comes to fruition," said Robert W. Atcher, Ph.D., M.B.A., chair of SNM's Domestic Isotope Availability Taskforce. "The time is now to make sure that the U.S. has long-term access to medical isotopes—without having to rely on foreign producers."
Molybdenum-99 (Mo-99) is a critical medical isotope. Technetium-99m—the decay product of Mo-99—is used in more than 16 million diagnostic medical tests annually in the U.S. for the early detection and effective management of cancer, heart disease, thyroid disease and other serious conditions. 
There are currently only six foreign producers of Mo-99 approved by the U.S. Food and Drug Administration to import the product into the U.S.—and no domestic facilities exist which are dedicated to the production of Mo-99 for medical uses. These aging foreign reactors regularly experience significant ongoing maintenance issues—frequently causing these reactors to go off-line. These continuing problems were exacerbated with reactors shutting down in Canada and the Netherlands earlier this year. Subsequently, the Canadian government announced that it will no longer produce medical isotopes as of 2016.
"To date, it has not been a pretty picture—and that is why SNM is so supportive of the House's approval of this bill," added Graham. 
Most reactors in the world that produce Mo-99 utilize highly enriched uranium (HEU), which can also be used in the construction of nuclear weapons. Under this legislation, nuclear reactors that produce Mo-99 would have to stop using HEU and make the transition to low enriched uranium (LEU) as a replacement. 
The American Medical Isotopes Production Act of 2009 now heads to the U.S. Senate for approval. If enacted, this legislation would create a stable and reliable supply of medical isotopes in the U.S. 
"This is landmark legislation for patients and all Americans," said Graham.
### 
About SNM—Advancing Molecular Imaging and Therapy
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated. 
SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snm.org. 

________________________________


      
_______________________________________________
You are currently subscribed to the RadSafe mailing list

Before posting a message to RadSafe be sure to have read and understood the RadSafe rules. These can be found at: http://radlab.nl/radsafe/radsaferules.html

For information on how to subscribe or unsubscribe and other settings visit: http://radlab.nl/radsafe/
CONFIDENTIAL AND PRIVILEGED INFORMATION NOTICE

This e-mail, and any attachments, may contain information that
is confidential, subject to copyright, or exempt from disclosure.
Any unauthorized review, disclosure, retransmission, 
dissemination or other use of or reliance on this information 
may be unlawful and is strictly prohibited.  

AVIS D'INFORMATION CONFIDENTIELLE ET PRIVILÉGIÉE

Le présent courriel, et toute pièce jointe, peut contenir de 
l'information qui est confidentielle, régie par les droits 
d'auteur, ou interdite de divulgation. Tout examen, 
divulgation, retransmission, diffusion ou autres utilisations 
non autorisées de l'information ou dépendance non autorisée 
envers celle-ci peut être illégale et est strictement interdite.


More information about the RadSafe mailing list